Coherus Partners Formycon/Bioeq File Ranibizumab With FDA

Company ‘Excited For Potential Approval In 2022’ For Lucentis Biosimilar

 
• By Dean Rudge

Launch planning is underway for the Lucentis biosimilar that Coherus BioScienes has in-licensed in the US from Formycon and Bioeq, the US-based firm has revealed, as the eye-disease biologic was submitted to the US Food and Drug Administration.

Washington, D.C., USA- January 13, 2020: FDA Sign outside their headquarters in Washington DC. The Food and Drug Administration (FDA or USFDA) is a federal agency of the USA.
Coherus is eyeing ranibizumab and adalimumab • Source: Shutterstock

More from Biosimilars

More from Products